Download presentation
Presentation is loading. Please wait.
Published byἸοκάστη Μελετόπουλος Modified over 6 years ago
1
Optimising Hormone Therapy in Advanced Disease
Laurent Boccon-Gibod European Urology Supplements Volume 4, Issue 8, Pages (November 2005) DOI: /j.eursup Copyright © Terms and Conditions
2
Fig. 1 A PSA DT of <3 months is statistically significantly associated with time to PCa specific survival [16]. D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst ;95(18):1376–1383, by permission of Oxford University Press. European Urology Supplements 2005 4, 21-29DOI: ( /j.eursup ) Copyright © Terms and Conditions
3
Fig. 2 A PSA DT of <3 months is statistically significantly associated with time to overall survival [16]. D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst ;95(18):1376–1383, by permission of Oxford University Press. European Urology Supplements 2005 4, 21-29DOI: ( /j.eursup ) Copyright © Terms and Conditions
4
Fig. 3 Overall survival after early or deferred therapy is similar in both groups [64]. Permission to reproduce has been granted by American Society of Clinical Oncology, 2004. European Urology Supplements 2005 4, 21-29DOI: ( /j.eursup ) Copyright © Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.